Type 2 Diabetes Connect
  • Saved

1yr
Safety and Efficacy of Canakinumab for the Prevention and Control of Type 2 Diabetes Mellitus and Its Complications: A Systematic Review - PubMed

Safety and Efficacy of Canakinumab for the Prevention and Control of Type 2 Diabetes Mellitus and Its Complications: A Systematic Review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39286685/

Today, diabetes mellitus (DM) is one of the leading causes of morbidity and mortality globally.In this grim context, while our current armamentarium of anti-diabetic agents is vast and increasingly available,...

Canakinumab, an anti-IL-1β antibody, modestly affects glycemic control in T2DM while significantly reducing inflammation and cardiovascular events, demonstrating safety and tolerability in patients.

  • Saved

1yr
The effectiveness of telemedicine in the management of type 2 diabetes: A systematic review - PubMed

The effectiveness of telemedicine in the management of type 2 diabetes: A systematic review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39263639/

Telemedicine may be a valuable solution for blood sugar management in patients with type 2 diabetes. However, the effectiveness of telemedicine in improving BMI and quality of life is unclear.

Telemedicine shows promise in managing blood sugar levels in type 2 diabetes, though its impact on BMI and quality of life remains uncertain.

  • Saved

1yr
Improving outcomes of type 2 diabetes mellitus patients in primary care with Chronic Care Model: A narrative review - PubMed

Improving outcomes of type 2 diabetes mellitus patients in primary care with Chronic Care Model: A narrative review - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38966652/

Designed and implemented over two decades ago, the Chronic Care Model is a well-established chronic disease management framework that has steered several healthcare systems in successfully improving the clinical outcomes...

The Chronic Care Model, with its six key elements, significantly enhances primary care for type 2 diabetes, improving patient outcomes and clinical practices over the past two decades.

  • Saved

1yr
True or false? Alzheimer's disease is type 3 diabetes: Evidences from bench to bedside - PubMed

True or false? Alzheimer's disease is type 3 diabetes: Evidences from bench to bedside - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38955264/

Globally, Alzheimer's disease (AD) is the most widespread chronic neurodegenerative disorder, leading to cognitive impairment, such as aphasia and agnosia, as well as mental symptoms, like behavioral abnormalities, that place...

This review explores the connection between Alzheimer's disease and type 2 diabetes, focusing on insulin resistance, Aβ, oxidative stress, and other mechanisms, aiming to uncover potential therapeutic strategies.

  • Saved

1yr
A patient with T2D and other cardiorenal risk factors

Mr. S is a 57-year-old man with a history of hypertension, chronic kidney disease (CKD), and dyslipidemia. He was recently diagnosed with type 2 diabetes (T2D). He is a former smoker (10 pack-year history) who admits to occasional alcohol consumption. His family history is notable for cardiovascular disease (CVD), and his father passed away from a myocardial infarction at the age of 62 years.

Mr. S is taking the following medications:

  • Thiazide diuretic
  • Angiotensin II receptor blocker
  • Calcium channel blocker
  • Statin
  • Ezetimibe
  • Bempedoic acid

Recent physical exam and laboratory findings include:

  • Body mass index 26 kg/m2
  • Blood pressure 124/72 mm Hg
  • Total cholesterol 175 mg/dL
  • Low-density lipoprotein cholesterol 70 mg/dL
  • Urine albumin-creatinine ratio 36 mg/g
  • Estimated glomerular filtration rate 62 mL/min/1.73m2
  • Fasting plasma glucose 188 mg/dL
  • Hemoglobin A1C 7.3%

Mr. S has been counseled on lifestyle modifications. As you consider pharmacotherapy for T2D, you are also concerned about his CKD and high risk for CVD, knowing that the 3 conditions are interrelated and mutually amplify morbidity and mortality.

Based on T2D guidelines, which class(es) of glucose-lowering medication would you recommend to help Mr. S achieve his glycemic goals while reducing his cardiorenal risk, and why?

Show More Comments